SCHEMBL401828

SCHEMBL401828

O=C(CNCc1ccccc1)Nc1ccc(C#Cc2ccccc2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.66
NPC1 O15118 2/20 0.58
RAB9A P51151 2/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
HTT P42858 2/20 0.58
ALDH1A1 P00352 4/20 0.55
KDM4E B2RXH2 3/20 0.55
MAPT P10636 2/20 0.55
GAA P10253 1/20 0.55
MGLL Q99685 1/20 0.54
LMNA P02545 2/20 0.52
HPGD P15428 1/20 0.52
NPY5R Q15761 1/20 0.51
PTPN1 P18031 1/20 0.49
PTPN6 P29350 1/20 0.49
PTPN11 Q06124 1/20 0.49
MEN1 O00255 1/20 0.49
CASP3 P42574 1/20 0.49
KMT2A Q03164 1/20 0.49
SENP7 Q9BQF6 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL403170 0.91 KDM4E (0.57) RECQLNPC1RAB9ASMN1; SMN2HTT
SCHEMBL27733545 0.91 RECQL (0.55) RECQLNPC1RAB9ASMN1; SMN2HTT
SCHEMBL402509 0.91 ALDH1A1 (0.57) RECQLNPC1RAB9ASMN1; SMN2HTT
SCHEMBL14874411 0.88 LTA4H (0.54) RECQLNPC1RAB9ASMN1; SMN2HTT
SCHEMBL27852723 0.86 RECQL (0.74) RECQLHTTALDH1A1KDM4EMAPT
SCHEMBL403072 0.84 RAB9A (0.68) RECQLNPC1RAB9ASMN1; SMN2HTT
SCHEMBL5864374 0.82 RECQL (0.69) RECQLNPC1RAB9AALDH1A1KDM4E
SCHEMBL400285 0.81 RAB9A (0.69) RECQLNPC1RAB9ASMN1; SMN2HTT
SCHEMBL15160744 0.81 RECQL (0.68) RECQLALDH1A1KDM4EMAPTGAA
SCHEMBL400098 0.80 RAB9A (0.63) NPC1RAB9ASMN1; SMN2HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4570317-A2 COMPOUNDS FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE Intervet International B.V. (NL) 2025-06-18 EP disclosed
US-12227485-B2 Compounds useful for the treatment of infection with Mannheimia haemolytica or Histophilus somni INTERVET INC. (US) 2025-02-18 US disclosed
US-12157717-B2 Compounds for the treatment of bovine or swine respiratory disease INTERVET INC. (US) 2024-12-03 US disclosed
US-12077488-B2 Compounds useful for treating a Mannheimia haemolytica or Histophilus somni infection INTERVET INC. (US) 2024-09-03 US disclosed
CN-110072844-B Compounds for the treatment of infection by Mannheimia haemolytica or histophilus somni 英特维特国际股份有限公司 2023-06-02 CN disclosed
US-20230000813-A1 COMPOUND FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE INTERVET INC. (US) 2023-01-05 US disclosed
CN-110300578-B Compounds for the treatment of respiratory diseases in cattle or pigs 英特维特国际股份有限公司 2022-12-13 CN disclosed
US-11406617-B2 Compounds for the treatment of bovine or swine respiratory disease INTERVET INC. (US) 2022-08-09 US disclosed
US-20220202786-A1 METHODS FOR TREATMENT OF CANCER MINERVA BIOTECHNOLOGIES CORPORATION (US) 2022-06-30 US disclosed
US-20220041547-A1 Compounds Useful for Treating a Mannheimia Haemolytica or Histophilus Somni Infection INTERVET INC. (US) 2022-02-10 US disclosed
WO-2004087153-A2 USE OF ORGANIC COMPOUNDS FOR IMMUNOPOTENTIATION CHIRON CORPORATION (US) 2004-10-14 WO disclosed
US-20040176385-A1 Small molecule PI 3-kinase inhibitors and methods of their use NOVARTIS AG (CH) 2004-09-09 US disclosed
WO-2004062601-A2 ANTIBACTERIAL AGENTS CHIRON CORPORATION (US) 2004-07-29 WO disclosed
WO-2004060308-A2 THIOSEMICARBAZONES AS ANTI-VIRALS AND IMMUNOPOTENTIATORS CHIRON CORPORATION (US) 2004-07-22 WO disclosed
US-20040122237-A1 Substituted benzazoles and methods of their use as inhibitors of Raf kinase NOVARTIS AG (CH) 2004-06-24 US disclosed
WO-2004048365-A1 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER CHIRON CORPORATION (US) 2004-06-10 WO disclosed
US-20040087626-A1 Substituted benz-azoles and methods of their use as inhibitors of Raf kinase NOVARTIS AG (CH) 2004-05-06 US disclosed
US-20040077707-A1 Pyrrole based inhibitors of glycogen synthase kinase 3 NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2004-04-22 US disclosed
WO-2004018455-A1 PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 CHIRON CORPORATION (US) 2004-03-04 WO disclosed
WO-2003082272-A1 SUBSTITUTED BENZAZOLES AND USE THEREOF AS RAF KINASE INHIBITORS CHIRON CORPORATION (US) 2003-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122237-A1 Substituted benzazoles and methods of their use as inhibitors of Raf kinase BRAF, RAF1, ARAF RECQL 1966/4885NPC1 4125/4885RAB9A 1662/4885
US-12077488-B2 Compounds useful for treating a Mannheimia haemolytica or Histophilus somni infection SORD, HEXD, SNRPD1 RECQL 385/4885NPC1 2418/4885RAB9A 2314/4885
US-20040087626-A1 Substituted benz-azoles and methods of their use as inhibitors of Raf kinase BRAF, RAF1, ARAF RECQL 1961/4885NPC1 4460/4885RAB9A 1810/4885
US-20220041547-A1 Compounds Useful for Treating a Mannheimia Haemolytica or Histophilus Somni Infection SORD, HEXD, SNRPD1 RECQL 385/4885NPC1 2418/4885RAB9A 2314/4885
US-12227485-B2 Compounds useful for the treatment of infection with Mannheimia haemolytica or Histophilus somni SORD, HEXD, SNRPD1 RECQL 428/4885NPC1 2835/4885RAB9A 2097/4885
US-20040176385-A1 Small molecule PI 3-kinase inhibitors and methods of their use PI4KB, PI4KA, PDPK1 RECQL 767/4885NPC1 666/4885RAB9A 778/4885
US-11406617-B2 Compounds for the treatment of bovine or swine respiratory disease PIGS, BTD, PPARD RECQL 739/4885NPC1 394/4885RAB9A 2231/4885
US-12157717-B2 Compounds for the treatment of bovine or swine respiratory disease PIGS, BTD, PPARD RECQL 487/4885NPC1 308/4885RAB9A 2139/4885
US-20040077707-A1 Pyrrole based inhibitors of glycogen synthase kinase 3 GSK3B, GSK3A, PYGB RECQL 3367/4885NPC1 2062/4885RAB9A 3754/4885
US-20220202786-A1 METHODS FOR TREATMENT OF CANCER TP53, TOP2B, BRCA1 RECQL 236/4885NPC1 445/4885RAB9A 3686/4885
US-20230000813-A1 COMPOUND FOR THE TREATMENT OF BOVINE OR SWINE RESPIRATORY DISEASE PIGS, BTD, BRD1 RECQL 945/4885NPC1 276/4885RAB9A 2082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.